A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

Neoplasms Malignant Clinical Trial

Official title:

A Phase 1a/1b, Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK112 in Subjects With Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04047290
• Other study ID #: AK112-101
• Status: Recruiting
• Phase: Phase 1
• Start date: September 20, 2019
• Est. completion date: August 30, 2024

Study information

• Verified date: October 2022
• Source: Akeso
• Contact: Baiyong Li
• Phone: +86 (0760) 8987 3999
• Email: global.trials[@]akesobio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of a dose escalation phase (Phase 1a) to determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for AK112 as a single agent, and a dose expansion phase (Phase 1b) in subjects with specific tumor types which will characterize treatment of AK112 as a single agent at the MTD or RP2D.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 151
• Est. completion date: August 30, 2024
• Est. primary completion date: June 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written and signed informed consent and any locally required authorization obtained from the subject/legal representative.

• In dose-escalation cohorts (Phase 1a), histologically or cytologically documented advanced or metastatic solid tumor that is refractory/relapsed to standard therapies, or for which no effective standard therapy is available, or the subject refuses standard therapy.

• In the dose-expansion cohorts (Phase 1b), histologically or cytologically confirmed selected advanced solid tumors.

• Subject must have at least one measurable lesion according to RECIST Version1.1.

• Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.

• Available archived tumor tissue sample to allow for correlative biomarker studies. If unavailable or unsuitable, the subject must consent and undergo fresh tumor biopsy.

• Adequate organ function.

• Subjects with central nervous system (CNS) metastases must have been treated, be asymptomatic.

• Females of childbearing potential and non-sterilized males who are sexually active must use an effective method of contraception from screening until 120 days after final dose of investigational product or women of non child bearing potential.

• Life expectancy =12 weeks.

Exclusion Criteria:

• History of severe hypersensitivity reactions to other mAbs.

• Prior malignancy active within the previous 3 years except for the tumor for which a subject is enrolled in the study, and locally curable cancers that have been apparently cured, (e.g. basal cell skin cancer, or carcinoma in situ of the cervix or breast).

• For subjects enrolled in the dose escalation phase, having received prior anti-PD-1, anti-PD-L1, anti-CTLA-4 or any other immunotherapy or immune-oncology (IO) agent within 28 days of commencing treatment with AK112 or experienced a toxicity that led to permanent discontinuation of prior immunotherapy. All AEs while receiving prior immunotherapy have not completely resolved or resolved to Grade 1 prior to screening, required the use of additional immunosuppression other than corticosteroids

• Receiving any immunotherapy, conventional or investigational systemic anticancer therapy within 4 weeks prior to the first dose

• Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment (hormones use for non-cancer related conditions is acceptable).

• Subjects with clinically significant cardiovascular disease

• Subjects with a condition requiring systemic treatment with either corticosteroid (> 10 mg daily ) or other immunosuppressive medications within 2 weeks of study drug administration.

• Current or recent use of aspirin (> 325 mg/day) or treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol.

• Current unstable of full-dose oral or parenteral anticoagulants or thrombolytic agents for > 2 weeks prior to the first dose of AK112

• Active or prior documented autoimmune disease within the past 2 years or conditions not expected to recur in the absence of an external trigger)

• Active or prior documented inflammatory bowel disease

• History of primary immunodeficiency.

• History of organ transplant.

• Known allergy or reaction to any component of the AK112 formulation.

• History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies.

• Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1

• Major surgical procedure within 30 days prior to the first dose of AK112 or still recovering from prior surgery.

• Known history of HIV.

• Known active hepatitis B or C infections. Note: Subjects with HCC and positive HBsAg result are eligible if the subjects were treated with antiviral therapy and HBV viral load less than 500 IU/mL prior to first dose of AK112.

• An active infection requiring systemic therapy

• Received live attenuated vaccination within 30 days prior to the first dose of AK112.

Related Conditions & MeSH terms

• Neoplasms
• Neoplasms Malignant

Intervention

Drug:
• AK112
AK112 is a PD1/VEGF bispecific antibody.

Locations

Country	Name	City	State
Australia	Border Medical Oncology	Albury	New South Wales
Australia	Monash Health	Clayton	Victoria
Australia	Adelaide Cancer Centre	Kurralta Park	South Australia
Australia	Peter MacCallum Cancer Centre	Melbourne	Victoria
Australia	Scientia Clinical Research Ltd	Randwick	New South Wales
Australia	ICON Cancer Foundation	South Brisbane	Queensland
Australia	Blacktown Hospital	Sydney	New South Wales

Sponsors (1)

Lead Sponsor	Collaborator
Akesobio Australia Pty Ltd

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and nature of participants with adverse events (AEs)	An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.	From time ICF is signed until 90 days after last dose of AK112
Primary	Number of participants with DLTs	DLTs will be assessed during the dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle (4 weeks) of treatment.	During the first four weeks of treatment with AK112
Secondary	Objective response rate (ORR)	The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1.	Up to 2 years
Secondary	Disease control rate (DCR)	The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD at 16 and 24 weeks respectively) based on RECIST Version 1.1.	Up to 2 years
Secondary	Progression-free survival (PFS)	Progression-free survival is defined as the time from the start of treatment with AK112 until the first documentation of disease progression or death due to any cause, whichever occurs first.	Up to 2 years
Secondary	Overall survival (OS)	Overall survival is defined as the time from the start of treatment with AK112 until death due to any cause.	Up to 2 years
Secondary	Area under the curve (AUC) of AK112 for assessment of pharmacokinetics	The endpoints for assessment of PK of AK112 include serum concentrations of AK112 at different timepoints after AK112 administration.	From first dose of AK112 through 90 days after last dose of AK112
Secondary	Maximum observed concentration (Cmax) and Minimum observed concentration (Cmin) of AK112	The endpoints for assessment of PK of AK112 include serum concentrations of AK112 at different timepoints after AK112 administration.	From first dose of AK112 through 90 days after last dose of AK112
Secondary	Number of subjects who develop detectable anti-drug antibodies (ADAs)	The immunogenicity of AK112 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs).	From first dose of AK112 through 90 days after last dose of AK112